CARLSBAD, Calif., Aug. 2, 2007 (PRIME NEWSWIRE) -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announces the following webcast:
What: Isis Pharmaceuticals' Second Quarter 2007 Financial
Results
When: Wednesday, August 8, 2007, at 4:30 p.m. ET /
1:30 p.m. PT
Where: www.isispharm.com
How: Live on the Internet. Simply log onto our website
listed above.
Contact: Kristina Lemonidis
Associate Director, Investor Relations
(760) 603-2331
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.